• 1
    The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:65561.
  • 2
    Paty D, Li DK; UBC/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. II. MRI analysis of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 1993; 43:6627.
  • 3
    Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De Jager P, Baecher-Allan C. Multiple sclerosis. Immunol Rev 2005; 204:20831.
  • 4
    Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type 1 interferons (α/β) in immunity and autoimmunity. Annu Rev Immunol 2005; 23:30736.
  • 5
    Biron CA. Interferons α and β as immune regulators – a new look. Immunity 2001; 14:6614.
  • 6
    Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc Natl Acad Sci USA 1998; 95:156238.
  • 7
    Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense. Function and regulation by innate cytokines. Ann Rev Immunol 1999; 17:189220.
  • 8
    Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 2005; 202:63750.
  • 9
    Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 1998; 8:5919.
  • 10
    Durbin JE, Fernandez-Sesma A, Lee CK et al. Type I IFN modulates innate and specific antiviral immunity. J Immunol 2000; 164:42208.
  • 11
    Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 5:124955.
  • 12
    Ito T, Amakawa R, Inaba M, Ikehara S, Inaba K, Fukuhara S. Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol 2001; 166:29619.
  • 13
    Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med 2000; 191:177788.
  • 14
    Lehuen A, Lantz O, Beaudoin L, et al. Overexpression of natural killer T cells protects Vα14-Jα281 transgenic nonobese diabetic mice against diabetes. J Exp Med 1998; 188:18319.
  • 15
    Miyamoto K, Miyake S, Yamamura TA. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing Th2 bias of natural killer T cells. Nature 2001; 413:5314.
  • 16
    Jahng A, Maricic I, Pedersen B, et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med 2001; 194:178999.
  • 17
    Singh A, Wilson M, Hong S et al. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med 2001; 194:180111.
  • 18
    Hong S, Wilson MT, Serizawa I et al. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001; 7:10526.
  • 19
    Sharif S, Arreaza G, Zucker P et al. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type-1 diabetes. Nat Med 2001; 7:105762.
  • 20
    Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005; 26:877900.
  • 21
    Illes Z, Kondo T, Newcombe J, Oka N, Tabira T, Yamamura T. Differential expression of NKT cell Vα24JαQ invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 2000; 164:437581.
  • 22
    Wilson S, Kent S, Patton K et al. Extreme Th1 bias of invariant Vα24JαQ T cells in type 1 diabetes. Nature 1998; 391:17781.
  • 23
    Yanagihara Y, Shiozawa K, Takai M, Kyogoku M, Shiozawa S. Natural killer (NK) T cells are significantly decreased in the peripheral blood of patients with rheumatoid arthritis (RA). Clin Exp Immunol 1999; 118:1316.
  • 24
    Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002; 110:793800.
  • 25
    Falcone M, Facciotti F, Ghidoli N et al. Up-regulation of CD1d expression restores the immunoregulatory function of NKT cells and prevents autoimmune diabetes in nonobese diabetic mice. J Immunol 2004; 172:590816.
  • 26
    Shi FD, Flodstrom M, Balasa B, Kim SH, Van Gunst K, Strominger JL, Wilson SB, Sarvetnick N. Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc Natl Acad Sci USA 2001; 98:677782.
  • 27
    Ohteki T, Yoshida H, Matsuyama T, Duncan GS, Mak TW, Ohashi PS. The transcription factor interferon regulatory factor 1 (IRF-1) is important during the maturation of natural killer 1.1+ T cell receptor-alpha/beta+ (NK1+ T) cells, natural killer cells, and intestinal intraepithelial T cells. J Exp Med 1998; 187:96772.
  • 28
    Raghuraman G, Geng Y, Wang C-R. IFN-β-mediated up-regulation of CD1d in bacteria-infected APCs. J Immunol 2006; 177:78418.
  • 29
    Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004; 4:2317.
  • 30
    Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 2002; 3:86774.
  • 31
    Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, Cebon J. Type 1 IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998; 161:194753.
  • 32
    Paquette RL, Hsu NC, Kiertscher SM, Park AN, Tran L, Roth MD, Glaspy JA. Interferon-alpha and granulocyte–macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol 1998; 64:35867.
  • 33
    Radvanyi LG, Banerjee A, Weir M, Messner HA. Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerate dendritic cell maturation from human peripheral blood mononuclear cells. Scand J Immunol 1999; 50:499509.
  • 34
    Wang C, Al-Omar HM, Radvanyi L, Banerjee A, Bouman D, Squire J, Messner HA. Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukaemia and enhancement of their T-cells stimulatory activity by IFN-alpha. Exp Hematol 1999; 27:117684.
  • 35
    Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F. Type 1 interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBMC-SCID mice. J Exp Med 2000; 191:177788.
  • 36
    Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, Borrow P, Tough DF. Type 1 interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 2002; 99:326371.
  • 37
    Marckmann S, Wiesemann E, Hilse R, Trebst C, Stangel M, Windhagen A. Interferon-β up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis. Clin Exp Immunol 2004; 138:499506.
  • 38
    Salomon B, Lenshow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12:43140.
  • 39
    Hayakawa Y, Takeda K, Yagita H, Van Kaer L, Saiki I, Okumura K. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J Immunol 2001; 166:60128.
  • 40
    Sonoda K-H, Exley M, Snapper S, Balk S, Stein-Streilein J. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J Exp Med 1999; 190:121526.
  • 41
    Denkers EY, Scharton-Kersten T, Barbieri S, Caspar P, Sher A. A role for CD4+ NK1.1+ T lymphocytes as major histocompatibility complex class II independent helper cells in the generation of CD8+ effector function against intracellular infection. J Exp Med 1996; 184:1319.
  • 42
    Gonzalez-Aseguinolaza GC. De Oliveira C, Tomaska M, et al. Alpha-galactosylceramide-activated Vα14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci USA 2000; 97:84616.
  • 43
    Flesch IE, Wandersee A, Kaufmann SH. IL-4 secretion by CD4+ NK1+ T cells induces monocyte chemoattractant protein-1 in early listeriosis. J Immunol 1997; 159:710.
  • 44
    Emoto M, Emoto Y, Buchwalow IB, Kaufmann SH. Induction of IFN-gamma-producing CD4+ natural killer T cells by Mycobacterium bovis bacillus Calmette–Guérin. Eur J Immunol 1999; 29:6509.
  • 45
    Kakimi K, Guidotti LG, Koezuka Y, Chisari FV. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000; 192:92130.
  • 46
    Grubor-Bauk B, Simmons A, Mayrhofer G, Speck PG. Impaired clearance of herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the semivariant V alpha 14-J alpha 281 TCR. J Immunol 2003; 170:14304.
  • 47
    Cui J, Shin T, Kawano T, et al. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278:16236.
  • 48
    Park SH, Kyin T, Bendelac A, Carnaud C. The contribution of NKT cells, NK cells, and other gamma-chain-dependent non-T non-B cells to IL-12-mediated rejection of tumors. J Immunol 2003; 170:1197201.
  • 49
    Shamshiev A, Donda A, Carena I, Mori L, Kappos L, De Libero G. Self glycolipids as T-cell autoantigens. Eur J Immunol 1999; 29:166775.